UB Paderborn / Katalog / Suche / in CDI

1 – 25 von 106

Sortiert nach

Effect of Fenofibrate on Kidney Function: A 6-Week Randomized Crossover Trial in Healthy People

American journal of kidney diseases, 2008-06, Vol.51 (6), p.904-913

2008

Volltextzugriff (PDF)

Predictive value of vascular endothelial growth factor polymorphisms for maintenance bevacizumab efficacy in metastatic colorectal cancer: an ancillary study of the PRODIGE 9 phase III trial

Therapeutic advances in medical oncology, 2022-01, Vol.14, p.17588359221141307-17588359221141307

2022

Volltextzugriff (PDF)

Bevacizumab Maintenance Versus No Maintenance During Chemotherapy-Free Intervals in Metastatic Colorectal Cancer: A Randomized Phase III Trial (PRODIGE 9)

Journal of clinical oncology, 2018-03, Vol.36 (7), p.674-681

2018

Volltextzugriff (PDF)

Prognostic variables in low and high risk stage III colon cancers treated in two adjuvant chemotherapy trials

European journal of cancer (1990), 2021-02, Vol.144, p.101-112

2021

Volltextzugriff (PDF)

Prognostic value of circulating tumour DNA in metastatic pancreatic cancer patients: post-hoc analyses of two clinical trials

British journal of cancer, 2022-02, Vol.126 (3), p.440-448

2022

Volltextzugriff (PDF)

Intratumor CMS Heterogeneity Impacts Patient Prognosis in Localized Colon Cancer

Clinical cancer research, 2021-09, Vol.27 (17), p.4768-4780

2021

Volltextzugriff (PDF)

Impact of G-CSF Prophylaxis on Chemotherapy Dose-Intensity, Link Between Dose-Intensity and Survival in Patients with Metastatic Pancreatic Adenocarcinoma

The oncologist (Dayton, Ohio), 2022-07, Vol.27 (7), p.e571-e579

2022

Volltextzugriff (PDF)

Efficacy of donepezil for the treatment of oxaliplatin-induced peripheral neuropathy: DONEPEZOX, a protocol of a proof of concept, randomised, triple-blinded and multicentre trial

BMC cancer, 2022-07, Vol.22 (1), p.1-742, Article 742

2022

Volltextzugriff (PDF)

Combination of CDX2 H-score quantitative analysis with CD3 AI-guided analysis identifies patients with a good prognosis only in stage III colon cancer

European journal of cancer (1990), 2022-09, Vol.172, p.221-230

2022

Volltextzugriff (PDF)

Efficacy of a docetaxel-5FU-oxaliplatin regimen (TEFOX) in first-line treatment of advanced gastric signet ring cell carcinoma: an AGEO multicentre study

British journal of cancer, 2018-08, Vol.119 (4), p.424-428

2018

Volltextzugriff (PDF)

Impact of time-varying cumulative bevacizumab exposures on survival: re-analysis of data from randomized clinical trial in patients with metastatic colo-rectal cancer

BMC medical research methodology, 2021-01, Vol.21 (1), p.14-14, Article 14

2021

Volltextzugriff (PDF)

Impact of laparoscopy on oncological outcomes after colectomy for stage III colon cancer: A post-hoc multivariate analysis from PETACC8 European randomized clinical trial

Digestive and liver disease, 2021-08, Vol.53 (8), p.1034-1040

2021

Volltextzugriff (PDF)

Neoadjuvant FOLFOX 4 versus FOLFOX 4 with Cetuximab versus immediate surgery for high-risk stage II and III colon cancers: a multicentre randomised controlled phase II trial--the PRODIGE 22--ECKINOXE trial

BMC cancer, 2015-07, Vol.15 (1), p.511, Article 511

2015

Volltextzugriff (PDF)

Is it still time for meta-analyses in operable esophageal cancers, or rather for a change of paradigm?

Journal of thoracic disease, 2017-10, Vol.9 (10), p.3594-3597

2017

Volltextzugriff (PDF)

The area between ROC curves, a non‐parametric method to evaluate a biomarker for patient treatment selection

Biometrical journal, 2020-10, Vol.62 (6), p.1476-1493

2020

Volltextzugriff (PDF)

Predictive factors for early progression during induction chemotherapy and chemotherapy-free interval: analysis from PRODIGE 9 trial

British journal of cancer, 2020-03, Vol.122 (7), p.957-962

2020

Volltextzugriff (PDF)

How to Balance Prognostic Factors in Controlled Phase II Trials: Stratified Permuted Block Randomization or Minimization? An Analysis of Clinical Trials in Digestive Oncology

Current oncology (Toronto), 2024-06, Vol.31 (6), p.3513-3528

2024

Volltextzugriff (PDF)

Postoperative circulating tumor DNA detection is associated with the risk of recurrence in patients resected for a stage II colorectal cancer

Frontiers in oncology, 2022-11, Vol.12, p.973167-973167

2022

Volltextzugriff (PDF)

Neoadjuvant radiotherapy combined with fluorouracil-cisplatin plus cetuximab in operable, locally advanced esophageal carcinoma: Results of a phase I-II trial (FFCD-0505/PRODIGE-3)

Clinical and translational radiation oncology, 2024-07, Vol.47, p.100804, Article 100804

2024

Volltextzugriff (PDF)

Construction of quality of life change patterns: example in oncology in a phase III therapeutic trial (FFCD 0307)

Health and quality of life outcomes, 2015-09, Vol.13 (1), p.151-151, Article 151

2015

Volltextzugriff (PDF)

1 – 25 von 106

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(105)
Mit Volltextzugriff
(104)

Publikationsform

Artikel
(106)

Sprache

Erscheinungsjahr

n.n

Thema

Life Sciences & Biomedicine
(56)
Science & Technology
(56)
Humans
(40)
Life Sciences
(40)
Oncology
(37)
Cancer
(36)
Female
(27)
Aged
(26)
Chemotherapy
(25)
Male
(25)
Middle Aged
(21)
Colorectal Cancer
(18)
Metastases
(18)
Adult
(16)
Antineoplastic Combined Chemotherapy Protocols - Therapeutic Use
(16)
Metastasis
(16)
Patients
(15)
Prognosis
(15)
Tumors
(14)
Gastroenterology & Hepatology
(13)

15 weitere anzeigen...

Weniger anzeigen...

Neu hinzugefügt

... seit 90 Tagen
(4)

Menü

Weitere Dienste

Einstellungen

Effect of Fenofibrate on Kidney Function: A 6-Week Randomized Crossover Trial in Healthy People

Baseline Splenic Volume as a Prognostic Biomarker of FOLFIRI Efficacy and a Surrogate Marker of MDSC Accumulation in Metastatic Colorectal Carcinoma

Predictive value of vascular endothelial growth factor polymorphisms for maintenance bevacizumab efficacy in metastatic colorectal cancer: an ancillary study of the PRODIGE 9 phase III trial

Early evaluation using a radiomic signature of unresectable hepatic metastases to predict outcome in patients with colorectal cancer treated with FOLFIRI and bevacizumab

Bevacizumab Maintenance Versus No Maintenance During Chemotherapy-Free Intervals in Metastatic Colorectal Cancer: A Randomized Phase III Trial (PRODIGE 9)

Bevacizumab plus FOLFIRI after failure of platinum–etoposide first-line chemotherapy in patients with advanced neuroendocrine carcinoma (PRODIGE 41-BEVANEC): a randomised, multicentre, non-comparative, open-label, phase 2 trial

Prognostic variables in low and high risk stage III colon cancers treated in two adjuvant chemotherapy trials

Prognostic value of circulating tumour DNA in metastatic pancreatic cancer patients: post-hoc analyses of two clinical trials

Intratumor CMS Heterogeneity Impacts Patient Prognosis in Localized Colon Cancer

Impact of G-CSF Prophylaxis on Chemotherapy Dose-Intensity, Link Between Dose-Intensity and Survival in Patients with Metastatic Pancreatic Adenocarcinoma

Efficacy of donepezil for the treatment of oxaliplatin-induced peripheral neuropathy: DONEPEZOX, a protocol of a proof of concept, randomised, triple-blinded and multicentre trial

Combination of CDX2 H-score quantitative analysis with CD3 AI-guided analysis identifies patients with a good prognosis only in stage III colon cancer

Lanreotide as maintenance therapy after first-line treatment in patients with non-resectable duodeno-pancreatic neuroendocrine tumours: An international double-blind, placebo-controlled randomised phase II trial – Prodige 31 REMINET: An FFCD study

Efficacy of a docetaxel-5FU-oxaliplatin regimen (TEFOX) in first-line treatment of advanced gastric signet ring cell carcinoma: an AGEO multicentre study

Impact of time-varying cumulative bevacizumab exposures on survival: re-analysis of data from randomized clinical trial in patients with metastatic colo-rectal cancer

Impact of laparoscopy on oncological outcomes after colectomy for stage III colon cancer: A post-hoc multivariate analysis from PETACC8 European randomized clinical trial

Neoadjuvant FOLFOX 4 versus FOLFOX 4 with Cetuximab versus immediate surgery for high-risk stage II and III colon cancers: a multicentre randomised controlled phase II trial--the PRODIGE 22--ECKINOXE trial

Is it still time for meta-analyses in operable esophageal cancers, or rather for a change of paradigm?

The area between ROC curves, a non‐parametric method to evaluate a biomarker for patient treatment selection

Predictive factors for early progression during induction chemotherapy and chemotherapy-free interval: analysis from PRODIGE 9 trial

How to Balance Prognostic Factors in Controlled Phase II Trials: Stratified Permuted Block Randomization or Minimization? An Analysis of Clinical Trials in Digestive Oncology

First-Line LV5FU2 with or without Aflibercept in Patients with Non-Resectable Metastatic Colorectal Cancer: A Randomized Phase II Trial (PRODIGE 25-FFCD-FOLFA)

Postoperative circulating tumor DNA detection is associated with the risk of recurrence in patients resected for a stage II colorectal cancer

Neoadjuvant radiotherapy combined with fluorouracil-cisplatin plus cetuximab in operable, locally advanced esophageal carcinoma: Results of a phase I-II trial (FFCD-0505/PRODIGE-3)

Construction of quality of life change patterns: example in oncology in a phase III therapeutic trial (FFCD 0307)

Suchergebnisse filtern